AUPH
Aurinia Pharmaceuticals Inc
$14.86
-0.33 (-2.17%)
quotes and stock data delayed 15 minutes
52 wk hi
52 wk low
11.34
20.37
Cash
$392M
Burn Rate (Qtr)
$34.1M
Mkt Cap
$1.9b
Avg Volume
3,814,933
*cash/burn updated:
Q3 '20
Company Profile
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
Catalyst Date
Recent Posts
See what the community is saying - click to see full post